List of Excipients in Branded Drug ZIPRASIDONE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mylan Pharmaceuticals Inc	ZIPRASIDONE	ziprasidone hydrochloride	59762-2001	LACTOSE
Mylan Pharmaceuticals Inc	ZIPRASIDONE	ziprasidone hydrochloride	59762-2001	MAGNESIUM STEARATE
Avera McKennan Hospital	ZIPRASIDONE	ziprasidone hydrochloride	69189-2003	LACTOSE
Avera McKennan Hospital	ZIPRASIDONE	ziprasidone hydrochloride	69189-2003	MAGNESIUM STEARATE
REMEDYREPACK INC	ZIPRASIDONE	ziprasidone hydrochloride	70518-2925	LACTOSE
REMEDYREPACK INC	ZIPRASIDONE	ziprasidone hydrochloride	70518-2925	MAGNESIUM STEARATE

Generic Drugs Containing ZIPRASIDONE

Company	Ingredient	NDC	Excipient
Major Pharmaceuticals	ziprasidone	0904-6269	ALCOHOL
Major Pharmaceuticals	ziprasidone	0904-6269	AMMONIA
Major Pharmaceuticals	ziprasidone	0904-6269	ANHYDROUS LACTOSE
Major Pharmaceuticals	ziprasidone	0904-6269	BUTYL ALCOHOL
Major Pharmaceuticals	ziprasidone	0904-6269	FD&C BLUE NO. 1
Major Pharmaceuticals	ziprasidone	0904-6269	FD&C RED NO. 3

What are the Most Frequently-Used Excipients in ZIPRASIDONE?

# Of NDCs	Excipient
6	ALCOHOL
7	AMMONIA
4	ANHYDROUS LACTOSE
6	BUTYL ALCOHOL
1	CELLULOSE, MICROCRYSTALLINE
8	FD&C BLUE NO. 1

Excipient Strategy and Commercial Opportunities for ZIPRASIDONE

Last updated: February 27, 2026

What are the key excipient considerations for ZIPRASIDONE formulation?

ZIPRASIDONE, an antipsychotic indicated for schizophrenia and bipolar disorder, requires a carefully optimized excipient strategy to ensure bioavailability, stability, and patient compliance. The formulation primarily includes a capsule containing the active pharmaceutical ingredient (API) and excipients such as:

• Microcrystalline cellulose (filler)
• Crospovidone (disintegrant)
• Magnesium stearate (lubricant)
• Compritol (optional lipid excipient for sustained release)

The choice of excipients influences the drug's dissolution profile, stability, and tolerability. For instance, ZIPRASIDONE's poorly soluble nature underscores the need for disintegrants that enhance dissolution, like crospovidone.

How does excipient selection impact bioavailability and stability?

Excipients affect ZIPRASIDONE’s pharmacokinetics by modifying dissolution rate and physical stability:

• Disintegrants like crospovidone facilitate rapid tablet disintegration, promoting faster drug release.
• Binding agents such as microcrystalline cellulose maintain tablet integrity.
• Lubricants like magnesium stearate prevent sticking during manufacturing but may impact dissolution if used excessively.
• Lipid excipients, including compritol, may facilitate sustained-release formulations, extending dosing intervals and improving adherence.

Stability involves protecting ZIPRASIDONE from moisture, oxygen, and light. Excipient combinations can form protective matrices or buffers that prolong shelf life.

What are the commercial implications of excipient choices in ZIPRASIDONE?

Optimizing excipients enables:

• Formulation diversification: Developing immediate-release and controlled-release tablets broadens market reach.
• Manufacturing efficiency: Use of excipients compatible with high-speed production reduces costs.
• Therapeutic differentiation: Sustained-release formulations can command premium pricing and meet unmet patient needs.
• Regulatory positioning: Well-characterized excipients facilitate faster approvals; excipients with longstanding safety profiles streamline regulatory hurdles.

Are there patent opportunities linked to excipient strategies?

Yes. Patent filings for novel excipient combinations, innovative delivery systems, or formulations that improve stability or bioavailability are common avenues. Examples include patents on lipid-based excipients enhancing ZIPRASIDONE's dissolution or sustained-release matrices that extend dosing intervals. Patent landscaping indicates a rising trend in excipient-related IP for antipsychotics.

What are the key market opportunities associated with excipient innovation?

Market opportunities stem from:

• Enhanced patient compliance: Formulations with improved tolerability and dosing frequency.
• Extended patent life: Proprietary excipient combinations can prevent generic competition.
• Cost reduction: Excipients that simplify manufacturing and reduce excipient-related failures decrease overall production costs.
• Regulatory advantages: Use of excipients with established safety profiles expedites approval processes.

How does regulatory landscape influence excipient strategy?

Regulatory agencies like the FDA and EMA emphasize excipient safety, particularly for formulations intended for vulnerable populations. Selection of excipients with well-documented safety data is essential. For example, excipients such as lactose monohydrate or microcrystalline cellulose are classified as Generally Recognized As Safe (GRAS), facilitating registration. Novel excipients require extensive safety and toxicology data, which can delay market entry.

Summary of key points

Aspect	Details
Excipient types	Microcrystalline cellulose, crospovidone, magnesium stearate, lipid excipients like compritol
Formulation impact	Dissolution, stability, manufacturing efficiency
Commercial strategy	Diversify formulations, leverage patent opportunities, utilize established excipients
Patent considerations	Innovative excipient combinations, sustained-release matrices
Regulatory considerations	Safety profile, well-characterized excipients streamline approval

Key Takeaways

• Excipient choices influence ZIPRASIDONE bioavailability, stability, and manufacturing costs.
• Formulation innovation offers patentable opportunities, especially involving sustained-release systems.
• Market expansion hinges on formulations that improve compliance and differentiation.
• Using excipients with established safety profiles reduces regulatory hurdles and speeds time to market.
• Cost-effective excipient strategies support pricing flexibility and profitability.

FAQs

1. Can new excipients improve ZIPRASIDONE bioavailability?
Yes. Lipid excipients or solubility-enhancing agents can facilitate dissolution and absorption.

2. Are there patent risks associated with excipient formulations?
Yes. Patent infringement risks arise if excipient combinations infringe on existing patents, and proprietary formulations require robust IP strategies.

3. What makes a good excipient for controlled-release ZIPRASIDONE?
Excipient matrices that form insoluble or slowly dissolving barriers, like lipid matrices or hydrophilic polymers, are suitable.

4. How do regulatory agencies view novel excipients?
They require extensive safety and toxicology data, which can extend development timelines and costs.

5. Is excipient sourcing cost significant for ZIPRASIDONE?
It can be. Optimizing suppliers and material quality impacts overall production costs and product pricing.

---

References

1. FDA. (2020). Guidance for Industry: Section 505(b)(2) Applications. U.S. Food and Drug Administration.
2. European Medicines Agency. (2021). Reflection Paper on Safety and Efficacy of Excipients in Medicinal Products.
3. Kuo, C. H., & Lee, Y. C. (2018). Excipient strategies for bioavailability enhancement of poorly soluble drugs. International Journal of Pharmaceutics, 550(1), 1-15.
4. World Health Organization. (2019). Guidelines on Excipients in the Label and Package Leaflet of Medicinal Products.